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a b s t r a c t
Elevated factor VIII levels have been established as thrombotic risk factor. In this case report,
we describe a 51 years old patient with a history of heart transplantation and acute
myocardial infarction, treated by stent implantation who presented with sub-acute stent
thrombosis. Elevated factor VIII levels were detected as most plausible cause of this
thrombotic event. A review of the literature is also performed.
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.Introduction
The prevalence of heart failure is increasing, and the prognosis
of end-stage heart failure remains dismal. At present time,
heart transplantation (HTx) remains the gold-standard thera-
py in this pathology [1]. The median survival for the entire* Corresponding author at  : Cardiology Department, Thorax Institute, Ho     
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0010-8650/# 2014 The Czech Society of Cardiology. Published by Elsecohort of adult heart recipients who receives an allograft is
approximately 11 years according to the Registry of the
International Society for Heart and Lung Transplantation
(ISHLT) [2].
Cardiac Allograft Vasculopathy (CAV) is the leading cause
of late morbidity and death among heart transplant recipients.
Angiographic studies indicate that CAV occurs in up to 42% ofspital Clinic, IDIBAPS, University of Barcelona, Villarroel 170, 08036        
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c o r e t v a s a 5 6 ( 2 0 1 4 ) e 3 1 1 – e 3 1 5e312all transplanted hearts, although by the use of more sensitive
techniques such as intravascular ultrasound (IVUS) or optical
coherence tomography this percentage may increase up to
75% of patients at 3 years after HTx [1].
CAV usually progresses rapidly and causes graft
failure. More uncommon is the occurrence of ST-segment
elevation myocardial infarction (STEMI) as clinical manifes-
tation of CAV [3]. Furthermore, little is known about the
outcomes of percutaneous treatment of STEMI in patients
with HTx [4].
In this case report, we present the case of an HTx
patient with a recent history of STEMI, treated by primary
percutaneous coronary intervention (PCI) who presented
with sub-acute stent thrombosis. A discussion of this clinical
scenario and a review of the potential etiology are also
performed.
Clinical case
A 51 years old male patient with a history of HTx at the age of
41 due to ischemic dilated cardiomyopathy was admitted due
to an acute coronary syndrome. Prior history only included one
episode of acute rejection that required intensive immuno-
suppressive therapy with cyclosporine followed by tacrolimus
and micofenolatus. A coronary angiography, performed as
control 17 months before, showed no signiﬁcant lesions in the
epicardial arteries, whereas left ventricular fraction ejectionFig. 1 – The ECG showed a complete right b(LVFE) measured by echocardiogram was around 55–60%. No
further events were reported during 10 years after HTx and the
patient remained in good general condition.
He was admitted, in our division, for atypical pain in the left
arm and dyspnea. The patient was in Killip-Kimball class II.
Duration of such symptoms was 24 h. The ECG (Fig. 1) showed
a complete right bundle branch block, known since one year
later HTx. Maximal troponin I was 110.5 ng/ml and creatine
kinase-MB 4.6 IU/l. Coronary angiography revealed a three-
vessel disease, with an acute thrombosis of proximal circum-
ﬂex artery as culprit vessel, TIMI grade 0, (Fig. 2A), a 70%
stenosis in a mid portion of left anterior descending artery
(LAD) and chronic total occlusion of a non dominant right
coronary artery. Primary PCI of the ‘‘culprit vessel’’ was then
performed by the use of manual aspiration thrombectomy and
bare metal stent implantation with good angiographic result
and TIMI grade 3 (Fig. 2B). The patient received 300 mg aspirin
and 600 mg clopidogrel as loading dose and 100 mg of aspirin
and 75 mg of clopidogrel daily as maintenance dose. Five days
later, the patient experienced sudden cardiac arrest due to
ventricular ﬁbrillation, requiring cardiopulmonary resuscita-
tion. A new angiography was immediately carried out
revealing stent thrombosis of circumﬂex artery, with TIMI
grade 3 (Fig. 3A and B). Manual aspiration of macroscopic
thrombotic material was performed followed by balloon
dilation with good angiographic result. Clopidogrel was
changed for prasugrel 10 mg SID. The patient was recovered
in the Coronary Care Unit and extubated 4 days later.undle branch block, known since HTx.
Fig. 2 – (A) Angiogram from right anterior oblique (RAO) caudal view prior to coronary intervention with an acute thrombosis
of proximal circumflex artery ‘‘culprit vessel’’, TIMI grade 0. (B) Angiogram after aspiration thrombectomy and implanted
bare metal stent with no residual stenosis and TIMI grade 3.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 3 1 1 – e 3 1 5 e313Echocardiogram performed at 7 days showed LVEF of 38% with
akinesia of infero-posterior and basal-lateral walls. Hematol-
ogy study was performed six months later revealing a high
level of coagulation factor VIII (216 U/dl; normal reference level
of 65–135 U/dl) as the only blood abnormality. At 6 months, the
patient remains in NYHA class II without new episodes of
coronary events and new echocardiogram showed LVEF
of 30%.Fig. 3 – (A and B) Angiogram showing stent thromDiscussion
CAV is the leading cause of late grafts failure following HTx [1].
According to ISHLT registry, incidence of CAV is around 10% at
1 year and reaches 50% at 5 years after HTx [3].
When acute myocardial infarction (AMI) occurs at a later
stage after HTx, it is most often related to CAV. Gao et al. inbosis of circumflex artery, with TIMI grade 3.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 3 1 1 – e 3 1 5e3141989 published the only study to date that speciﬁcally
addresses the incidence of late AMI following HTx. Among
329 heart transplant recipients at Stanford, 22 were found to
develop MI at a mean time of 3.9 years after transplantation [5].
Besides, there are few case reports of ST elevation myocardial
infarction following HTx as presentation of CAV [6–11].
Several factors may explain the apparently low incidence of
MI following HTx. Under-reporting by patients due to lack of
angina pectoris from the denervated heart may likely play a
role. The sensation of angina during myocardial ischemia is
generally thought to require functional sympathetic afferent
ﬁbers [12]. Although there exist some reports in human and
animal models of spontaneous sympathetic re-innervation
years after transplantation, heart transplant recipients usually
do not present with typical anginal symptoms [13]. Dyspnea,
fatigue, rate or rhythm changes or even sudden death may be
the only early clinical symptoms and signs of AMI [14,15].
Therefore, it is not uncommon for HTx to present massive
myocardial infarction similar to this case and yet not
experience any chest pain. In our case the patient experienced
AMI requiring late primary percutaneous coronary interven-
tion (PCI) and bare metal stent implantation. Despite good
initial angiographic result, the patient suffered from subacute
stent thrombosis leading to ventricular ﬁbrillation and subse-
quent cardiac arrest.
PCI in patients with HTx who develop CAV has been
associated with greater restenosis rates compared to PCI in
patients with native coronary artery disease [4,16]. Use of the
ﬁrst generation drug eluting stents (DES) appears to reduce
the incidence of in-stent restenosis in CAV as compared with
bare metal stents [17–20], but they do not appear to improve
the clinical end points of death and major adverse cardiac
events as stent thrombosis [21,22].
We herein report the ﬁrst case of an HTx patient with
documented elevation of factor VIII (FVIII) level who sequen-
tially presented two thrombotic events: a STEMI, treated by
stent implantation (PCI) followed by sub-acute stent thrombo-
sis. High FVIII levels are common risk factor for deep venous
thrombosis and may also be associated with risk of arterial
thrombosis in coronary heart disease and stroke [23]. Apart from
ABO blood group, no genetic components have been associated
with plasma FVIII levels. The main determinant is an elevated
von Willebrand factor (vWF) level [24]. However FVIII may have
some effect independent of vWF. Few acquired factors such as
active infections, speciﬁc treatments (micofenolatus) or acute-
phase reaction may also increase FVIII levels [23,25]. Compared
with tests for venous thrombophilia that must be performed a
minimum of 6 weeks after the acute thrombotic event, tests for
arterial thrombophilia are much less susceptible to the effects of
acute thrombosis and could be performed soon after an acute
thrombotic event [26]. Besides, some studies demonstrated that
a high FVIII level may persist over time, beyond the acute phase
state [27,28]. In any case, our blood analysis was performed well
beyond the acute phase of MI and the theoretical window of
acute inﬂammatory reaction.
Elevated FVIII levels have been established as thrombotic
risk factor after endovascular intervention for peripheral
arterial disease and also after lung transplantation [29,30].
In particular, elevated FVIII levels were encountered in 5 out of
6 patients suffering from thromboembolic events after lungtransplantation [30]. But, up to date, no cases have been
described in patients receiving HTx. In our clinical case,
however, we cannot completely rule out the presence of
resistance to aspirin or clopidogrel as no platelet function test
was performed after stent thrombosis.
In conclusion, AMI in HTx patients may have misleading
clinical manifestation. A high degree of clinical suspicion has
to be maintained in the event of subtle ECG changes and
atypical chest pain. Besides, stent thrombosis may also
develop in such scenario where the prothrombotic milieu of
the acute coronary syndrome, together with elevated FVIII
levels converges. In the case of any thrombotic event after
HTx, complete haematologic analysis that includes FVIII levels
should be performed.
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